Nanobodies as novel agents for cancer therapy
Top Cited Papers
- 1 January 2005
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Biological Therapy
- Vol. 5 (1) , 111-124
- https://doi.org/10.1517/14712598.5.1.111
Abstract
Nanobodies are the smallest fragments of naturally occurring heavy-chain antibodies that have evolved to be fully functional in the absence of a light chain. As such, the cloning and selection of antigen-specific nanobodies obviate the need for construction and screening of large libraries, and for lengthy and unpredictable invitro affinity maturation steps. The unique and well-characterised properties enable nanobodies to excel conventional therapeutic antibodies in terms of recognising uncommon or hidden epitopes, binding into cavities or active sites of protein targets, tailoring of half-life, drug format flexibility, low immunogenic potential and ease of manufacture. Moreover, the favourable biophysical and pharmacological properties of nanobodies, together with the ease of formatting them into multifunctional protein therapeutics, leaves them ideally placed as a new generation of antibody-based therapeutics. This review describes the state of the art on nanobodies and illustrates their potential as c...Keywords
This publication has 111 references indexed in Scilit:
- The intracellular antibody capture technology (IACT): towards a consensus sequence for intracellular antibodiesJournal of Molecular Biology, 2002
- Efficient tumor targeting by single‐domain antibody fragments of camelsInternational Journal of Cancer, 2002
- Lateral recognition of a dye hapten by a llama VHH domainJournal of Molecular Biology, 2001
- Stability engineering of antibody single-chain Fv fragmentsJournal of Molecular Biology, 2001
- Molecular Dynamics Simulations Highlight Mobile Regions in Proteins: A Novel Suggestion for Converting a Murine VH Domain into a More Tractable SpeciesJournal of Molecular Biology, 2000
- Canonical antigen-binding loop structures in immunoglobulins: more structures, more canonical classes?Journal of Molecular Biology, 2000
- Camel heavy-chain antibodies: diverse germline VHH and specific mechanisms enlarge the antigen-binding repertoireThe EMBO Journal, 2000
- Recent advances in the large-scale production of antibody fragments using lower eukaryotic microorganismsResearch in Immunology, 1998
- Solution properties ofEscherichia coli-expressed VH domain of anti-neuraminidase antibody NC41Protein Journal, 1995
- ‘Camelising’ human antibody fragments: NMR studies on VH domainsFEBS Letters, 1994